The primarily objective of this study is to assess the effect of switching from Tenofovir Disoproxil Fumurate (TDF) to TAF based ART on bone mass and turnover among women on DMPA for contraception. HIV virologically suppressed women on DMPA will be switched from their TDF based regimen to Bictergravir /Emtricitabine / Tenofovir alafenamide (B/F/TAF; Biktarvy) in a randomized fashion. HIV infected women on TDF and non-hormonal contraception will be switched to Biktarvy).
| Condition | Bone Loss |
|---|---|
| Treatment | B/F/TAF, DMPA, TDF/3TC/EFV or DTG or NVP |
| Clinical Study Identifier | NCT03916328 |
| Sponsor | MU-JHU CARE |
| Last Modified on | 7 June 2023 |
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer
Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!
No annotations made yet
Congrats! You have your own personal workspace now.